Introduction
Treatment options for patients with chronic obstructive pulmonary disease (COPD) such as inhaled bronchodilators (eg, long-acting muscarinic antagonists [LAMAs] and long-acting β 2 -agonists [LABAs] ) and inhaled corticosteroids (ICS) are central to the pharmacological management of COPD. 1 LAMAs have been shown to improve lung function, relieve symptoms, increase exercise capacity, improve quality of life (QoL), and reduce COPD exacerbations to a greater extent than shortacting bronchodilators or placebo. [1] [2] [3] [4] Combination therapies containing ICS/LABAs are a recommended treatment option for patients with severe COPD or those at a high risk of exacerbations, and have been shown to improve both lung function and QoL, as well as reducing COPD exacerbations, compared with monotherapy components or placebo. 1, 5, 6 According to current COPD treatment guidelines, an incremental approach to pharmacological treatment of COPD is recommended, involving the use of treatment combinations with different or complementary mechanisms of action. 1, 7 Evidence suggests that open-triple therapy that incorporates a LAMA with ICS/LABA combination products, administered via separate delivery devices, may be beneficial in improving lung function and QoL in patients with COPD. [8] [9] [10] [11] Triple therapy is becoming increasingly important in clinical practice, with one analysis showing that ~20% of patients with COPD in the United States were using triple therapy over a 12-month period ending in 2012. 12 However, there has been minimal research on clinical characteristics or previous treatment patterns of patients initiating triple therapy. In addition, there is limited "realworld" information available regarding time to initiation of open-triple therapy, particularly in patients who have pulmonary-function testing (PFT) information available. To better understand patient groups that may benefit from this treatment option, it is important to assess the treatment patterns and clinical characteristics prior to initiation of open-triple therapy in real-world practice.
This retrospective study of patients with COPD, newly initiated on LAMA monotherapy or ICS/LABA combination therapy, assessed the clinical characteristics and time to initiation of open-triple therapy. Post hoc analyses of these data in subsets of patients with PFT information and patients with and without comorbid asthma were also performed.
Material and methods study design
This observational study (GSK study number: HO-13-13008) retrospectively assessed the time to initiation of open-triple therapy in patients with COPD who were initiated on longacting inhaled therapy. Sources of patient data included health insurance claims and electronic medical records (EMR) from the Reliant Medical Group (RMG; Worcester, MA, USA), the Lovelace Health Plan (LHP), and Presbyterian Health Plan (PHP) (both Albuquerque, NM, USA 
end points and assessments
Baseline demographics and clinical characteristics evaluated during the 12 months prior to the index date (defined as the first use of LAMA or ICS/LABA) included smoking status, severity of COPD obstruction assessed by PFT, Charlson comorbidities based on ICD-9 codes, 15 specific respiratory-related comorbidities, and baseline medications. Exacerbation history at baseline was also assessed. Time to (and rate of) initiation of open-triple therapy (defined as a LAMA administered concomitantly with ICS/LABA therapy for 30 days of treatment) was evaluated for 12 months after the index date.
Among patients with PFT information, a forced expiratory volume in 1 second/forced vital capacity (FEV 1 /FVC) ratio of 0.7 was required for a diagnosis of COPD to be confirmed, and severity (based on Global initiative for chronic 
statistical analyses
Baseline assessments were summarized for between-cohort comparisons. The descriptive comparisons of the LAMA and ICS/LABA cohorts were prespecified; the post hoc analyses of patients with available spirometry data, and patients with and without comorbid asthma, used the same statistical methods as in the main analyses. All analyses were conducted using SAS version 9.2 or STATA version 10.0.
Descriptive statistics were used to summarize the observation period, the time to open-triple therapy, and the rates of treatment initiation at different time points following the index date. These data were compared between the cohorts initiated on LAMA or ICS/LABA. Categorical variables were assessed using Pearson Chi-square tests. Continuous variables were assessed using Student's t-tests.
Time to and rate of initiation of open-triple therapy (including the additional post hoc analyses of patients with PFT information and patients with and without comorbid asthma) were compared between cohorts using KaplanMeier analysis, and statistical significance assessed using log-rank tests.
Results

Patient demographics and clinical characteristics
In total, 1,463 and 2,259 patients were identified as newly initiated on LAMA monotherapy or ICS/LABA combination therapy, respectively (Table 1 ). In total, 208 (72.7% of 286) and 555 (74.5% of 745) RMG patients in the LAMA and ICS/ LABA cohorts had EMR and claims information available, respectively. A total of 268 (26% of 1,031) RMG patients (in both cohorts) only had EMR information available. Overall, baseline demographics were similar across cohorts; the mean age was ~71 years and 53%-55% of patients were female. Information on smoking status was unavailable for the majority of patients in each cohort. However, in patients where data were available, the proportion of current-, former-, or nonsmokers was similar between cohorts. PFT information was available for 371 (25%) patients in the LAMA cohort and 679 (30%) patients in the ICS/LABA cohort, and 269 (18%) and 447 (20%) patients had confirmed COPD (Table 1) . Additionally, there were 324 (22.1%) patients with asthma in the LAMA cohort and 775 (34.3%) in the ICS/LABA cohort, leaving 1,139 (77.9%) patients without asthma in the LAMA cohort and 1,484 (65.7%) in the ICS/LABA cohort. A similar proportion of patients experienced moderate-to-very severe COPD in each cohort (Table 1) .
During the 12-month baseline period, the LAMA cohort had a significantly lower proportion of patients with 2 respiratory-related comorbidities compared with the ICS/ LABA group ( Table 1 (Table 1) .
Overall, demographics and clinical characteristics were generally similar between treatment cohorts in the subsets of patients who had PFT information available and with or without comorbid asthma (Table 2) . However, among those with PFT information available, patients initiating on LAMA compared with ICS/LABA were significantly older and a significantly lower percentage were female.
Baseline exacerbations
During the 12-month baseline period, 283 (19.3%) and 160 (10.9%) patients in the LAMA cohort had a history of moderate and severe exacerbations, compared with 482 (21.3%) and 289 (12.8%) patients in the ICS/LABA cohort, respectively (Table 3) .
Similar results were observed in patients who had PFT information available and patients without comorbid asthma (ie, a slightly higher proportion of patients had moderate or severe exacerbations at baseline in the ICS/LABA versus the LAMA cohort). No significant differences were identified in the proportions of patients with moderate or severe exacerbations at baseline between the ICS/LABA and LAMA cohorts in patients with PFT information or patients with comorbid asthma. However, in patients without asthma, the proportion of patients with severe exacerbations at baseline was significantly higher in the ICS/LABA cohort than in the LAMA cohort (Table 4 ).
Time to initiation of open-triple therapy
A significantly higher proportion of patients in the LAMA cohort initiated open-triple therapy compared with the ICS/LABA cohort (Table 5) . Results were similar (also significant) in patients who had PFT information available and patients with and without asthma; in patients who had PFT information available and patients with asthma, considerably greater proportions of patients in the LAMA cohort initiated open-triple therapy than in the overall population ( Table 5) the closest pulmonary function test to the index date was used to assess COPD obstruction severity. Abbreviations: COPD, chronic obstructive pulmonary disease; ICs, inhaled corticosteroid; laBa, long-acting β 2 -agonist; laMa, long-acting muscarinic antagonist; saBa, short-acting β-agonist; saMa, short-acting muscarinic antagonist; sD, standard deviation.
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Mapel et al less time to initiation than the ICS/LABA cohort. Patients without asthma had similar times to initiation to patients in the prespecified analysis; again, patients in the LAMA cohort had significantly less time to initiation than the ICS/LABA cohort ( Table 5 ). The Kaplan-Meier analyses showed that patients in the LAMA cohort had a significantly higher rate of open-triple therapy initiation compared with patients in the ICS/LABA cohort at 12 months (Figure 1 ). Among patients with PFT information available, a significantly higher rate of initiation of open-triple therapy was also observed in the LAMA cohort compared with the ICS/LABA cohort at 12 months (Figure 2) . Additionally, in patients with asthma, the LAMA cohort had a significantly higher rate of open-triple therapy initiation compared with those in the ICS/LABA cohort at 12 months; the difference between cohorts was greater than in the overall population (Figure 3) . In patients without asthma, the LAMA cohort again had a significantly higher rate of open-triple therapy initiation compared with the ICS/LABA cohort at 12 months, but the difference between cohorts was less than in the overall population (Figure 4) .
Discussion
This observational study retrospectively assessed the time to initiation of open-triple therapy in patients with COPD who were initiated on long-acting inhaled bronchodilator or long-acting bronchodilator plus ICS combination therapy. Additional post hoc analyses for initiation of open-triple therapy in patients who had PFT information available were also performed. Sensitivity analyses were also performed for initiation of open-triple therapy in patients with and without a potential asthma comorbidity.
Overall, the crude percentage of patients with COPD initiated on LAMA monotherapy who augmented to opentriple therapy was twice that of patients with COPD initiated on ICS/LABA therapy. This difference was apparent in the first few months after the index date and was significant in the prespecified analyses; similar findings were observed in the post hoc analyses of patients with available PFT information and patients with and without asthma. Moreover, rate and time-to-event analyses showed that open-triple therapy initiation was also significantly different in the LAMA cohort compared with the ICS/LABA cohort. Again, similar results were observed in the subsets of patients with available PFT information and patients with and without asthma. Other observational studies have indicated that up to 25% of patients with COPD receiving maintenance mono-or combination therapies (either LAMA or ICS/LABA, respectively) may switch to, or concomitantly receive, other long-acting treatments. [16] [17] [18] This may be due to an actual or perceived lack of efficacy.
In line with these findings, the data presented here provide real-world evidence that patients with COPD are more likely to initiate open-triple therapy following initiation with LAMA monotherapy, compared with ICS/LABA therapy. This advance to triple therapy was less likely among patients receiving ICS/LABA even though they had more indications of disease instability during the pre-index period, such as a higher incidence of moderate and severe COPD exacerbations and increased rate of "rescue or baseline" inhaler use. In addition, there were considerably more patients on ICS/LABA therapy than LAMA therapy at baseline. This preference in starting treatment might suggest a lower threshold for adding an ICS/LABA to LAMA therapy, compared with adding a LAMA to ICS/LABA therapy. As the GOLD guidelines state that prescriptions of bronchodilator therapy for patients with COPD should be "on an as-needed or regular basis to prevent or reduce symptoms," these findings may indicate that unspecified factors (other than moderate or severe exacerbation events) are a driving factor for clinical decisions to advance to triple therapy more quickly on LAMA versus ICS/LABA. Indeed, other clinical factors 
1833
Open-triple therapy in patients with COPD of monotherapy can be predictive of subsequent treatment adherence or changes to treatment. 20 It is also possible that other agents could be added to either LAMA or ICS/LABA therapy as an alternative to progression to ICS/LABA/LAMA triple therapy. For example, the phosphodiesterase-4 inhibitor roflumilast has been shown to improve patient outcomes when added to both LAMA monotherapy 21 and ICS/LABA such as adverse events (eg, the risk of acute urinary retention potentially associated with use of LAMAs in men with benign prostatic hyperplasia 19 ), or nonclinical factors such as patient satisfaction with treatment, may not be easily captured in utilization databases but could also affect clinical treatment decisions. Findings from a previous study suggest that clinical characteristics and events presenting long before the initiation combination therapy. 22 While roflumilast use in this study was very low (1%), and therefore would not have substantially affected the overall findings, it would be interesting to assess the rates of addition of alternative treatments in future studies. The increasing awareness of the potential benefits of LAMA/LABA combination therapy versus LAMA or LABA monotherapy 23, 24 has introduced an alternative route to triple therapy with the subsequent addition of ICS to a LAMA/ LABA combination. Limited data are currently available comparing the efficacy of triple therapy with LAMA/LABA therapy; 1, 9, 25 however, it would be interesting to compare the rate of escalation to triple therapy from LAMA/LABA combinations with those from LAMA or ICS/LABA therapies. As such, additional research examining the factors influencing physician treatment decisions and patient treatment experience in COPD is warranted.
A limitation of this study is that claims databases may contain inaccuracies or omissions, particularly with respect to procedures or diagnoses. It should also be noted that a proportion of the RMG patient data were only available through EMR; therefore, information on health care services obtained outside of the group may be missing. In addition, not all prescriptions reported may have been used by the patients. As the results were collected from patients from the USA only, further evidence is required to demonstrate that these findings apply to wider patient populations. Finally, as the incidence of initiation of open-triple therapy was 25% in either cohort, the calculation of time-to-event is less robust than would be the case if 50% of the population augmented to open-triple therapy; consequently, the differences observed between cohorts should be viewed with caution.
Conclusions
Overall, the results of this analysis show that patients in the study population with COPD receiving LAMA monotherapy are more likely to initiate open-triple therapy than those receiving ICS/LABA. These findings were consistent between patients who had a primary or secondary diagnosis of COPD, those with PFT information, and those with and without comorbid asthma. Further research is required to identify clinical or nonclinical factors associated with treatment augmentation in patients with COPD.
